Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 188

Sort by

Sort Order Select

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2024-197897

Published: 2024

Journal Articles

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Juan Rangel-Patiño, John Kuruvilla, Anca Prica, Robert Kridel, Sita D. Bhella, Vishal Kukreti, Jan Delabie, Abi Vijenthira, Manjula Maganti, Michael Crump

Blood (2024) 144 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2024-210922

Published: 2024

Journal Articles

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Chathuri Abeyakoon, Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood (2024) 144 (Supplement 1): 1695.

https://doi.org/10.1182/blood-2024-201189

Published: 2024

Journal Articles

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inna Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood (2024) 144 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2024-206056

Published: 2024

Journal Articles

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Davidson Zhao, Victoria Shelton, Inna Gong, Juan Rangel-Patiño, Ting Liu, Michael Hong, Vanessa Murad, Ur Metser, Anca Prica, Vishal Kukreti, Sita Bhella, Abi Vijenthira, Michael Crump, John Kuruvilla, Bernard Lam, Robert Kridel

Blood (2024) 144 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2024-199677

Published: 2024

Journal Articles

Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL

Daisy V. Tran, Evelyn Teh, Susanne Penny, Devanand M. Pinto, Samuel D. Saibil, John Kuruvilla, Rob C. Laister

Blood (2024) 144 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2024-203618

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Tomohiro Aoki, Davidson Zhao, Noémie Lang, Yifan Yin, Ting Liu, Michael Hong, Johanna Regala, Troy Ketela, Anca Prica, John Kuruvilla, Pedro Farinha, Jan Delabie, Federico Gaiti, Kerry J. Savage, David W. Scott, Robert Kridel

Blood (2024) 144 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2024-194926

Published: 2024

Journal Articles

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Rintu Sharma, John Kuruvilla, Michael Crump, David Hodgson, Yangqing Deng, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Rodger E Tiedemann, Sita Bhella, Chloe Yang, Anca Prica

Blood (2024) 144 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2024-212184

Published: 2024

Journal Articles

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Tiana Kordbacheh, Anca Prica, Kelvin KW Chan, Mahmood Aminilari, Zharmaine Ante, Ning Liu, Inna Y Gong, Sita D. Bhella, Michael Crump, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine I Chen, Vishal Kukreti, Chloe Yang, Nauman Malik, David Hodgson, Danielle Rodin

Blood (2024) 144 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2024-201539

Published: 2024

Journal Articles

Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma

Kyla L. Trkulja, Will Tong, Daisy V. Tran, Li Meng, Evelyn Teh, Susanne Penny, Devanand M. Pinto, Armand Keating, John Kuruvilla, Rob C. Laister

Blood (2024) 144 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2024-208314

Published: 2024

Journal Articles

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Blood (2024) 144 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2024-209364

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

Single-Cell Immuno-Metabolic Profiling of Apheresis Samples for Chimeric Antigen T Cell Receptor Therapy Using Cytometry By Time of Flight

Inna Y Gong, Rowena Rodrigo, Giselle M Boukhaled, Daisy V. Tran, Tiana Coley, Babak Noamani, Evelyn Teh, Devanand M. Pinto, Ben X Wang, John Kuruvilla, Samuel D. Saibil, Rob C. Laister

Blood (2024) 144 (Supplement 1): 7144.

https://doi.org/10.1182/blood-2024-206502

Published: 2024

Journal Articles

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Randeep Sangha, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Erwan Beauchamp, Jay M. Gamma, Naveen Pemmaraju, Gautam Borthakur, Luc G. Berthiaume, John R. Mackey

Blood (2024) 144 (Supplement 1): 5791.

https://doi.org/10.1182/blood-2024-208480

Published: 2024

Journal Articles

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Blood (2024) 144 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2024-205736

Published: 2024

Journal Articles

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Adam Suleman, Michael Crump, Graeme Andrew McCrae Fraser, Robert Kridel, Sita D. Bhella, Chloe Yang, Vishal Kukreti, Stephen Ronan Foley, Tom Kouroukis, Amaris Balitsky, John Kuruvilla, Abi Vijenthira, Gwynivere A Davies, Anca Prica

Blood (2024) 144 (Supplement 1): 6281.

https://doi.org/10.1182/blood-2024-198044

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

NARROW

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma

Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis

Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada

Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma

Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Single-Cell Immuno-Metabolic Profiling of Apheresis Samples for Chimeric Antigen T Cell Receptor Therapy Using Cytometry By Time of Flight

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience

Outcomes of Patients with Primary Central Nervous System Lymphoma Treated with Matrix Followed By High-Dose Chemotherapy and Autologous Stem Cell Transplant - a Multicentre, Retrospective Study

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only